



The relative strengths and weaknesses of Aerovate Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aerovate Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Aerovate Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 307%, being 229% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	174,333
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,550
Liabilities, Non-Current	382
Other Assets	844
Other Compr. Net Income	-59
Other Expenses	3.0
Other Liabilities	13
Other Net Income	62
Other Revenues	0
Property and Equipment	186
Research and Development	14,987
Selling, General and Administrative Expense	8,035

Output Variable	Value in 1000 USD
Assets	175,363
Liabilities	2,945
Expenses	23,025
Revenues	0
Stockholders Equity	172,418
Net Income	-22,963
Comprehensive Net Income	-22,992
Economic Capital Ratio	307%